A cell therapy sorted down to specific cell types more than doubled a transplant outcome

The Food and Drug Administration approved Tregzi, known clinically as Orca-T, on 30 June — the first approval in the United States for a cell therapy built by sorting donor blood into specific, purified cell populations rather than transplanting a donor's blood cells largely as collected [s1].

Tregzi is approved for use alongside matched-donor hematopoietic stem cell transplantation with a myeloablative preparative regimen — the intensive chemotherapy or radiation regimen that clears a patient's own bone marrow before a donor transplant — in adults with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or mixed-phenotype acute leukemia [s1]. The approved use is specifically to support blood and immune system reconstitution and to improve chronic graft-versus-host-disease-free survival [s1].

What makes the manufacturing different

A standard allogeneic stem cell transplant infuses a donor's collected blood cells largely as harvested. Tregzi instead separates a matched donor's cells into three defined populations before infusion: hematopoietic stem and progenitor cells, which reconstitute the blood and immune system; highly purified regulatory T cells, intended to suppress the graft-versus-host reaction that occurs when donor immune cells attack the recipient's tissue; and conventional T cells, dosed to support both immune reconstitution and the graft-versus-leukemia effect that helps prevent cancer relapse [s1]. Each dose is prepared individually for the matched donor-recipient pair rather than manufactured as a standardized off-the-shelf product [s1].

The premise is that graft-versus-host disease and the desirable graft-versus-leukemia effect are driven by different components of a donor's immune cells, and that separating and individually dosing those components can suppress the harmful reaction without giving up the beneficial one. The trial data are the test of whether that premise holds in practice.

What the trial found

Approval rests on the Precision-T study, a randomized, open-label, multi-center Phase 3 trial of 187 patients with a median age of 43.6 years (range 19 to 65), comparing Tregzi plus tacrolimus against conventional allogeneic transplant plus tacrolimus and methotrexate — a standard graft-versus-host prevention regimen [s1].

At 12 months, the trial's primary endpoint — chronic graft-versus-host-disease-free survival — was 78% in the Tregzi group versus 38% in the conventional-transplant group [s1]. Secondary outcomes moved in the same direction: chronic GVHD itself occurred in 13% of Tregzi patients versus 44% on the conventional arm; overall survival at 12 months was 94% versus 83%; a combined measure of GVHD-free and relapse-free survival was 63% versus 31%; and non-relapse mortality was 3% versus 13% [s1]. Rates of severe acute GVHD (grade 3–4) were somewhat lower with Tregzi, 6% versus 10%, as were rates of grade 3 or higher infections, 44% versus 51% [s1].

Every one of those comparisons favors Tregzi, and by a wide margin on the primary endpoint — more than double the chronic-GVHD-free survival rate of the conventional-transplant comparator. That is an unusually large effect size for a single randomized trial in transplant medicine, and it is the basis on which FDA approval was granted; this article draws no conclusion beyond what the manufacturer's reported trial results show, since independent, peer-reviewed publication of the full trial data was not available at the time of approval.

What the therapy still carries as risk

Tregzi's approval includes serious warnings common to allogeneic transplant generally: graft failure, acute and chronic GVHD (including fatal cases, despite the therapy's design to reduce chronic GVHD incidence), infusion reactions including anaphylaxis, secondary malignancies, post-transplantation lymphoproliferative disorder, and the risk of transmitting infectious agents from donor to recipient [s1]. The most common adverse reactions reported include mucositis, diarrhea, rash, viral, bacterial and fungal infections, abdominal pain, vomiting, nausea, hemorrhage, and acute GVHD [s1]. A precision manufacturing process narrows one category of risk; it does not eliminate the broader risks inherent to intensive conditioning and allogeneic transplant.

What clinicians are saying

Miguel-Angel Perales, chief of the adult bone marrow transplant service at Memorial Sloan Kettering Cancer Center, called the approval a sign of "a new era in transplant medicine" [s1]. Robert Negrin, professor of medicine at Stanford Medicine, described it as "a defining moment for the transplant community," specifically because it is the first FDA approval for a therapy built on highly purified regulatory T cells [s1]. Nate Fernhoff, Orca Bio's co-founder and chief executive, framed the approval as resting on "decades of pioneering science" into how donor immune cells can be separated and recombined [s1]. All three quotes come from the company's own approval announcement.

What to watch

Whether independent, peer-reviewed publication of the full Precision-T results, including detailed statistical analysis, confirms the magnitude of benefit reported in the company's summary. How Tregzi's individualized, per-patient manufacturing process affects turnaround time and access compared with conventional transplant, particularly at centers without existing cell-processing infrastructure. And whether real-world outcomes, tracked outside the controlled trial setting, sustain the gap in chronic-GVHD-free survival seen in Precision-T.

This article is informational and is not medical advice. Decisions about transplant therapy belong with a hematology-oncology team familiar with an individual patient's disease and donor match.